Pablo Umaña

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

Ekkehard Mössner, Peter Brünker, Samuel Moser et al. · Blood · 2010 · 929 citations · Full text

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

Pablo Umaña, Joël Joan Pierre Jean-Mairet, Radmila Moudry et al. · Nature Biotechnology · 1999 · 755 citations

Engineered Glycoforms, Medicine, Immunology +10

Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

Claudia Ferrara, Sandra Grau, Christiane Jäger et al. · Proceedings of the National Academy of Sciences · 2011 · 735 citations

Glycobiology, Immunology, Immunotherapeutics +20

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni et al. · Journal of Clinical Oncology · 2021 · 392 citations · Full text

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

Tilman Schlothauer, Sylvia Herter, Claudia Ferrara et al. · Protein Engineering Design and Selection · 2016 · 388 citations · Full text

Immunology, Immune Regulation, Immunodominance +24